Avis d'AGA et rapport annuel
Publication of Notice of Annual General Meeting and Annual Report
Dublin, London | 5 April 2024: Uniphar plc (le "Entreprise"Ou"Uniphar") wishes to announce that it is today posting to shareholders its Notice of Annual General Meeting ("AGA") for 2024 together with its annual report and accounts for the year ended 31 December 2023 ("Rapport annuel"). The AGM will be held at 11.00 a.m. on 9 May 2024 at the offices of William Fry LLP, 2 Grand Canal Square, Dublin 2, D02 A342.
Uniphar values the participation of its shareholders at its AGM and encourages all shareholders to take part in the meeting either in person or by voting and raising questions in advance.
The Notice of Meeting, Form of Proxy and Annual Report are available to view on the Company's website at https://www.uniphar.ie/static/investors/shareholder-centre/AGM/AGM-2024 and will be available for inspection during normal business hours on any business day from today until the conclusion of the AGM at the registered office of the Company.
Proxy voting can be carried out in advance of the AGM. Details of how to do so are set out in further detail in the Notice of Meeting.
A conference call facility will be provided to allow shareholders to listen live to the business of the AGM. Please note that you will not be able to use this facility to vote, raise points or issues or ask questions. If you wish to listen live to the AGM proceedings, you can register for the conference call and receive participant log-in details at https://www.uniphar.ie/static/investors/shareholder-centre/AGM/AGM-2024 Shareholders availing of this facility should ensure to submit any votes in advance of the meeting as it will not be possible to vote using the conference call facility.
Shareholders are invited to submit questions in writing in advance of the meeting either by email to [email protected] or by post to the Company Secretary, Uniphar plc, 4045 Kingswood Road, Citywest Business Park, Co. Dublin, D24 V06K, Ireland. Questions must be received by 11.00 a.m. sur 7 mai 2024. Shareholders must include their Shareholder Reference Number (as set out on their Form of Proxy) with any question submitted.
Informations de contact
Groupe Uniphar
| Tel: + 353 (0) 1 428 7777 |
Allan Smylie, responsable de la stratégie et des RI | |
Davy (Société conjointe Broker, conseiller désigné et Sponsor de la cotation d'Euronext Growth)
| Tel: + 353 (0) 1 679 6363 |
Daragh O'Reilly Niall Gilchrist Ivan Murphy | |
RBC Marchés des Capitaux Broker)
| Tel: + 44 (0) 20 7653 4000 |
Jamil Miah Rupert Walford | |
Stifel Nicolaus Europe Limited (entreprise commune Broker)
| Tel: +44 (0) 20 7710 7600 |
Matt Blavat Ben Madison François Nord | |
RP Q4
| Tel: + 353 (0) 1 475 1444 |
Iarla Mongey, conseillère en relations publiques du groupe Uniphar |
À propos d'Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.
La vision de la Société est d'améliorer l'accès des patients aux produits et traitements pharmaco-médicaux en améliorant la connectivité entre les fabricants et les acteurs de la santé. Uniphar représente une solide combinaison d'échelle, de croissance et de rentabilité.
Chaîne d'approvisionnement et vente au détail d'Uniphar
Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.
Uniphar Medtech
Uniphar Medtech est l'un des principaux distributeurs paneuropéens de dispositifs médicaux et partenaire de solutions. La stratégie du Groupe pour Uniphar Medtech consiste à développer notre offre de services à travers l'Europe et à élargir notre marché potentiel en servant de nouvelles spécialités et de nouveaux fabricants.
Uniphar Pharma
Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.